The new results demonstrate the efficacy of Amep when administered intramuscularly. Amep prompted a 53% reduction in tumor growth (proof of concept established in a melanoma model).
Amep, a plasmid coding for a peptide which binds to surface receptors on tumor cells, is a novel anti-invasive cancer therapy. In October 2007, BioAlliance announced highly promising results for Amep administered directly within tumors.
Dominique Costantini, CEO of BioAlliance Pharma, said: “This new administration route demonstrates that Amep has a global, systemic effect and broadens the perspectives for treatments, in particular for metastatic melanoma. BioAlliance is gathering data to prepare the clinical trial application.”